02190 ZYLOXTB-B
- 10.420
- -0.140-1.33%
ZYLOXTB-B News
Guichuang Tongqiao-B (02190.HK) nominated Dr. Qian Xiang as an independent non-executive director candidate
Gelonghui, May 9 | Guichuang Tongqiao-B (02190.HK) announced that due to his other positions, Mr. Liang Hongze has indicated that he will not be re-elected as an independent non-executive director at the company's recent annual general meeting of shareholders. As a result, Mr. Leung will no longer serve as an independent non-executive director and member of the Company's Audit Committee and Remuneration Committee after the Annual General Meeting of Shareholders. Based on the recommendations of the company's nomination committee, the board of directors has also reviewed and decided to nominate Dr. Qian Xiang as an independent non-executive director candidate for the second board of directors.
Hong Kong Stock Concept Tracking | Favorable Policies Drive Continued Demand Expansion, Domestic Medical Device Companies Usher in Development Opportunities (with concept stocks)
Guodu Securities believes that overall, as the medical sector implements equipment renewal actions, it will drive the release of domestic demand for medical equipment.
Baili Tianheng and Shenzhou Cell turned losses into profits! Many biomedical companies on the Science and Technology Innovation Board ushered in a “good start” in Q1
In the first quarter of 2024, many parts of the country successively issued relevant policies to support the high-quality development of the biomedical industry or innovative pharmaceutical devices to continuously optimize the biomedical innovation environment.
歸創通橋-B：年報 2023
Express News | Guichuangtong talks on “EU launches medical device procurement market entry survey in China”: limited impact on the field of high-value consumables for vascular intervention
Repurchase Collection on April 17 | HSBC Holdings, Hang Seng Bank, etc. bought back one after another, of which HSBC Holdings spent HK$226 million
According to HKEx's April 18 disclosure documents, $HSBC Holdings (00005.HK) $ and $Hang Seng Bank (00011.HK) $ repurchased shares. ① $HSBC Holdings (00005.HK) $ repurchased 3.6 million common shares on April 16, involving an amount of HK$226 million. The repurchase price per share ranged from HK$63.05 to HK$62.25. ② $Hang Seng Bank (00011.HK) $ repurchased 600,000 common shares on April 17, involving an amount of HK$57.427,600. The repurchase price per share ranged from HK$96.65 to 94.9
Guichuang Tongqiao-B (02190) bought back 4000 shares on April 17
Guichuang Tongqiao-B (02190) announced that on April 17, 2024, the company spent HK$38,000...
Repurchase Collection on April 16 | HSBC Holdings, Changshi Group, etc. bought back one after another, of which HSBC Holdings spent HK$206 million
According to documents disclosed by the Hong Kong Stock Exchange on April 17, $HSBC Holdings (00005.HK) $, $Changshi Group (01113.HK) $, etc. repurchased shares. ① $HSBC Holdings (00005.HK) $ repurchased 3.2412 million common shares on April 15, involving an amount of HK$206 million. The repurchase price per share ranged from HK$63.85 to HK$63.1. ② $Changshi Group (01113.HK) $ repurchased 2,434,500 common shares on April 16, involving an amount of HK$76.3271 million, with a repurchase price of HK$31.4 per share
Guichuang Tongqiao-B (02190.HK) spent HK$933,000 to buy back 104,000 shares on April 16
Gelonghui, April 16 | Guichuang Tongqiao-B (02190.HK) announced that it spent HK$933,000 to repurchase 104,000 shares on April 16, at a price of HK$8.78-9.09 per share.
The results for the full year of 2023 were announced. What was the performance of innovative medical device companies under the collection test?
Hengqiang, the strongest in innovative medical devices
Selected announcements | CNPC's net profit last year exceeded 160 billion yuan; Pharmaceutical Federation's annual profit increased by more than 80% year-on-year
China Overseas Hongyang Group: Net profit of 2023 was 2.02 billion yuan, down 26.94% year on year; Zero Sports Auto: 2023 revenue of 16.747 billion yuan, up 35.22% year on year; Tencent Holdings: spent HK$1,001 billion to buy back 3.47 million shares on March 25.
Guichuang Tongqiao (02190.HK): Intensive launch of a variety of new products drives performance growth and further increases market share in collection and release
Incident: The company announced its 2023 annual results, achieving operating income of 528 million yuan (+58.0%), net profit to mother of 7.873 million yuan (+30.7%), deducting 7.033 million yuan (+1) from non-return mother
Guichuang Tongqiao-B (02190.HK): The State Drug Administration approved the launch of the Tongqiao Kirin blood flow guide device
On March 25, Gelonghui | Guichuang Tongqiao-B (02190.HK) announced that the Tongqiao Kirin blood flow guidance device independently developed by the Group has been approved for listing by the China Drug Administration (“State Drug Administration”). As the first fully developed remote closed dense mesh stent made in China, the Tsuqiao Kirin blood flow guide device will not only bring new treatment options for intracranial aneurysm treatment; at the same time, it will further enrich the company's product portfolio matrix and enhance the company's influence in the field of neurovascular interventional treatment in China. As of the date of this announcement, the company has obtained approval from the State Drug Administration for a total of 41 products in China. According to the disclosure, blood
Zylox-Tonbridge Shrinks Loss by 31% in Fiscal 2023
Zylox-Tonbridge Medical Technology (HKG:2190) recorded a 30.7% decline in attributable loss for the year ended Dec. 31, 2023, to 78.7 million yuan from 113.6 million yuan in 2022, a Friday filing on t
Press Release: Zylox-Tonbridge Announces Annual Financial Results for 2023, Demonstrating Robust Growth and Improved Profitability
HANGZHOU, China, March 22, 2024 /PRNewswire/ -- Zylox-Tonbridge Medical Technology Co., Ltd. (2190. HK), a leading medical device company in the peripheral and neurovascular interventional market in China, announced its annual financial results for 2023.
Guichuang Tongqiao-B (02190.HK): Performance is in line with expectations, domestic alternatives continue to be verified
The 2023 results are in line with our expectations: revenue of $528 million, +58% year over year; adjusted net profit of 7.03 million yuan (adjusted loss of 25.88 million yuan in 2022). revenues
Guichuang Tongqiao (2190.HK): Revenue growth slightly exceeds expectations in 2023, and the dense net stent is expected to be approved within the year
The company's revenue growth in 2023 slightly exceeded expectations and achieved its first profit under the adjusted net profit scale. Although gross margin has declined slightly due to the reduction in collection prices, and the trend may continue, we believe that the scale effect brought about by collection will gradually be reflected and superimposed
Guichuang Tongqiao (02190) has excellent results in 2023: operating revenue increased 58% to 530 million yuan to achieve profit under the adjusted net profit scale
Along with the expansion of revenue scale and overall improvement in operating efficiency, Guichuang Tongqiao achieved an adjusted net profit of 7.03 million yuan in 2023.
ZYLOXTB-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Guichuang Tongqiao-B (02190.HK) plans to hold a board meeting on March 21 to approve the annual results
Gelonghui March 8 | Guichuang Tongqiao-B (02190.HK) announced that the company will hold a board meeting on March 21, 2024 (Thursday) to review and approve the annual results and announcements of the company and its subsidiaries for the year ended 31 December 2023, and to deal with other matters.
Analysis
Price Target
No Data
